NEW YORK (Standard&Poor's) Nov. 27, 2013--Standard&Poor's Ratings Services said today that its ratings on CVS Caremark Corp. (BBB+/Stable/A-2) are unaffected by the company's acquisition of Coram LLC. CVS announced that it has entered into an agreement to acquire Coram LLC for about $2.1 billion from Apria Healthcare Group Inc. Coram, the specialty infusion services and enteral nutrition unit of Apria, is expected to generate about $1.4 billion in revenues during the first 12 months following the close of the deal. After considering one time transaction and integration costs, this transaction is expected to have an immaterial impact on CVS' financial results in 2014. We believe the acquisition of Coram enhances CVS' position in the growing specialty
